For research use only. PeptaBase is for informational and laboratory research reference only. No medical claims are made and nothing on this site is intended to diagnose, treat, cure or prevent any disease.
PeptaBase
500+ PubMed CitationsNo Affiliate LinksPrivate & Secure
Category Authority

GH Secretagogues: Research Overview

Growth hormone secretagogues are studied for pituitary signaling, pulsatile GH release, IGF-1 modulation, and protocol timing research.

What Are GH Secretagogues

Growth hormone secretagogues are peptides and related compounds studied for their ability to influence growth-hormone release through pituitary or ghrelin-related signaling pathways. In research discussions, this category commonly includes GHRH analogs, ghrelin receptor agonists, and compounds often paired together in protocol planning. PeptaBase treats them as a distinct authority group because the literature often compares these peptides by pulse timing, half-life, receptor pathway, and downstream IGF-1 logic rather than by headline use case alone.

Mechanisms Studied

Mechanisms studied here typically center on pulsatile GH release, GHRH signaling, ghrelin-receptor agonism, downstream IGF-1 modulation, recovery-related endocrine effects, and timing-sensitive pharmacodynamic behavior. A peptide may look similar to another on the surface, yet act through a meaningfully different upstream pathway. Structured category context helps clarify those differences, especially when one compound is researched for prolonged stimulation and another is studied more for short-acting secretagogue behavior or protocol stacking logic.

Common Compounds

Common compounds in this category include CJC-1295, Ipamorelin, Sermorelin, Hexarelin, GHRP-2, GHRP-6, MK-677, and Tesamorelin. Some have clinical or marketed contexts, while others remain more strongly associated with experimental or protocol-focused research. Because these compounds are frequently mentioned together, category-level authority content is useful for separating receptor pathway, administration cadence, and study maturity from the simplified way secretagogues are often described elsewhere online.

Research Evidence

The evidence base across GH secretagogues is varied. Some compounds have formal clinical history and better characterized pharmacology, while others are cited more through research use, protocol communities, or narrower study sets. PeptaBase presents this category with evidence labels, species context, and internal links to each peptide page so readers can move from the broader secretagogue framework into the specific compound literature with better context and less overgeneralization.

Peptides in This Category

CJC without DAC (MOD-GRF)
GH pulsatility studies|IGF-1 axis modulation|Recovery and sleep research|Combination GHS protocols
CJC-1295 DAC
Long-acting GH secretagogue research|IGF-1 elevation studies|Body-composition models|Recovery protocols
GHRP-2
GH release studies|IGF-1 modulation|Appetite and ghrelin research|Combination secretagogue protocols
GHRP-6
GH release and appetite studies|Ghrelin signaling|Recovery protocols|Body-composition research
Hexarelin
GH release studies|Cardioprotection research|Ghrelin-receptor pharmacology|Body-composition models
HGH 191AA
GH replacement research|IGF-1 elevation studies|Body composition investigations|Bone density and turnover
Ipamorelin
Selective GH release research|Sleep/recovery studies|IGF-1 modulation|Combination peptide protocols
Ipamorelin/CJC-1295 No DAC Blend
Ipamorelin and CJC-1295 No DAC combination|GH pulsatility studies|Combined secretagogue protocol|Recovery and sleep research
MK-677
GH/IGF-1 axis studies|Sleep and recovery research|Appetite signaling|Body-composition research
Sermorelin
GH deficiency testing/support|IGF-1 axis modulation|Body-composition research|Recovery and sleep studies
Tesamorelin
HIV-associated lipodystrophy research|Visceral-fat reduction|GH axis studies|NAFLD and body-composition research